CARB-X
Biotechnology Research • 
771e Commonwealth Ave, Boston, United States • 21-50 Employees
Company overview
| Headquarters | 771e Commonwealth Ave, Boston, Massachusetts 02215, US |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2016 |
| Employees | 21-50 |
| Socials |
Key Contacts at CARB-X
Kevin Outterson
Executive Director
Ed T. Buurman
Alliance Director - Vaccines And Biotherapeutics
Will Hall
Director Of External Affairs
Tina Mercado-Bradford
Associate Director, Financial Systems & Reporting
Vega Masignani
Alliance Director
Elizabeth Amiott
Alliance Director
Kevin Outterson
Executive Director
CARB-X Email Formats
CARB-X uses 4 email formats. The most common is {first name}{last name} (e.g., johndoe@bu.edu), used 44.8% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@bu.edu | 51.7% |
{first name} | john@bu.edu | 31% |
{last name} | doe@bu.edu | 17.2% |
About CARB-X
CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University and its funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services; the Wellcome Trust, a global charity based in the UK; Germany’s Federal Ministry of Education and Research (BMBF); the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (UK GAMRIF); the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) within the HHS. CARB-X is investing more than $500 million from 2016-2021 to support innovative antibiotics and other therapeutics, vaccines and rapid diagnostics. CARB-X supports the world’s largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X focuses exclusively on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is headquartered at Boston University School of Law.
CARB-X revenue & valuation
| Annual revenue | $3,336,645 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $10,700,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
CARB-X has 18 employees across 9 departments.
Departments
Number of employees
Funding Data
CARB-X has never raised funding before.
CARB-X Tech Stack
Discover the technologies and tools that power CARB-X's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
UI frameworks
WordPress plugins
SEO
Frequently asked questions
4.8
40,000 users
